NCT00398957View on ClinicalTrials.gov

An Open-Label Evaluation of the Dose Proportionality of OROS� Hydromorphone HCL Tablets 8mg, 16mg, 32mg, 64mg

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

Not specified

Study Completion Date

September 30, 1998

Conditions
Analgesia
Interventions
DRUG

OROS® Hydromorphone HCL; OROS® Dilaudid; Dilaudid SR (slow release); Naltrexone (an opioid antagonist).

All Listed Sponsors
lead

Alza Corporation, DE, USA

INDUSTRY

NCT00398957 - An Open-Label Evaluation of the Dose Proportionality of OROS� Hydromorphone HCL Tablets 8mg, 16mg, 32mg, 64mg | Biotech Hunter | Biotech Hunter